bioAffinity Technologies, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BIAF Nasdaq 2836 www.bioaffinitytech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for bioAffinity Technologies, Inc.

bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung - Jan 13th, 2025 1:00 pm
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Jan 10th, 2025 2:00 pm
bioAffinity Technologies Boosts Sales with CyPath Lung - Dec 21st, 2024 11:33 am
Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19 - Dec 17th, 2024 1:00 pm
bioAffinity Technologies Set for Continued Expansion in 2025 - Dec 12th, 2024 1:00 pm
Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule - Dec 5th, 2024 1:00 pm
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 - Nov 14th, 2024 1:00 pm
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development - Nov 4th, 2024 1:00 pm
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung - Oct 30th, 2024 12:00 pm
WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement - Oct 21st, 2024 3:39 pm
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement - Oct 21st, 2024 2:45 pm
WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement - Oct 18th, 2024 6:57 pm
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement - Oct 18th, 2024 4:45 pm
bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines - Oct 16th, 2024 12:00 pm
bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer - Oct 10th, 2024 12:00 pm
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test - Oct 9th, 2024 12:00 pm
Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis - Sep 18th, 2024 12:00 pm
bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO - Aug 23rd, 2024 9:15 pm
bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales - Aug 14th, 2024 1:25 pm
bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million - Aug 5th, 2024 5:17 pm